US Patent

US9987261 — Substituted diazaspiroalkanes as androgen receptor modulators

Formulation · Assigned to University of California San Diego UCSD · Expires 2027-03-27 · 1y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects compounds useful for preventing or treating hyperproliferative diseases or disorders.

USPTO Abstract

Described herein, inter alia, are compounds useful for the prevention or treatment of hyperproliferative diseases or disorders.

Drugs covered by this patent

Erleada (apalutamide) · Johnson & Johnson

Patent Metadata

Patent number: US9987261
Jurisdiction: US
Classification: Formulation
Expires: 2027-03-27
Drug substance claim: No
Drug product claim: Yes
Assignee: University of California San Diego UCSD
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.